Raphael Pharmaceutical

Discover RaphaWell, a once-daily CBG and sesame oil product with clear directions, preliminary research context, and secure PayPal checkout.

Discover RaphaWell, its once-daily directions, ingredients, preliminary research context, and secure PayPal checkout.

Explore Raphael’s research programs with their documented status, available evidence and historical context.

The page details Raphael’s rheumatoid arthritis research, a proof-of-concept study, and the source records defining its findings and limitations.

Browse Raphael Pharmaceutical company news, peer-reviewed research, company reports and public filing resources with clear source labels.

Read Raphael Pharmaceutical company updates and scientific materials, with links to the underlying public sources.

Browse Raphael’s scientific publication and study-material records, including source links and verification qualifications.

Raphael Pharmaceutical introduces its leadership and scientific advisory team, including biographies and role details.

Find Raphael’s public corporate governance information and the status of company-approved governance documents.

The page provides public investor governance resources and a pathway for accessing authorized investor materials.

Raphael Pharmaceutical describes its scientific focus, mission, and leadership.

Contact Raphael Pharmaceutical for corporate, investor, product, partnership, affiliate, media or research inquiries.

Send a RaphaWell product question or feedback to the Raphael Pharmaceutical support team.

Explore Raphael Pharmaceutical, its cannabinoid science, leadership, RaphaWell product, investor resources, partnerships, news and publications.

Raphael Pharmaceutical partners with AIcreatesAI to deploy AI-driven managed services across operations and growth initiatives. The collaboration, under an Annual Managed Services Agreement starting July 30, 2026, aims to accelerate digital transformation and operational efficiency. AIcreatesAI will provide expertise to integrate AI capabilities into Raphael’s workflows.

Sep 2026TradingViewNews article

Raphael Pharmaceutical (OTC: RAPH) names a new chief financial officer amid recent shifts in its board composition. The company does not disclose the individual’s identity or background. These changes follow broader restructuring efforts at the firm.

Jul 2026KalkineNews article

Raphael Pharmaceutical files a provisional patent for a therapy targeting neutrophil-dominant autoimmune diseases, including rheumatoid arthritis. The move follows research into novel mechanisms for addressing inflammatory conditions driven by neutrophil activity. The company’s focus aligns with unmet needs in treating chronic autoimmune disorders where conventional treatments fall short.

Nov 2025GlobeNewswireNews article

Raphael Pharmaceutical reports positive proof-of-concept clinical trial results for its cannabinoid-based formula targeting rheumatoid arthritis. The study demonstrates early efficacy in treating symptoms associated with the autoimmune condition. The company develops plant-derived therapeutic solutions for chronic inflammatory diseases.

Jan 2025GlobeNewswireNews article